Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition
Journal of Medicinal Chemistry · 08.08.2024 · 67 (15) · 12521-12533
DOI: 10.1021/acs.jmedchem.4c00403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.07.2024. Verfasst von Jian'ai Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 21000…. Hauptthemen laut MEDLINE: Ferroptosis, Iron, Nuclear Receptor Coactivators. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province, Science Fund for Distinguished Young Scholars of Jiangsu Province.
Abstract (Originalsprache)
Ferroptosis, a distinctive form of programmed cell death, has been implicated in numerous pathological conditions, and its inhibition is considered a promising therapeutic strategy. Currently, there is a scarcity of efficient antagonists for directly regulating intracellular ferrous iron. Ferritinophagy, an essential process for supplying intracellular labile iron, relies on nuclear receptor coactivator 4 (NCOA4), a selective autophagy receptor for the ferritin iron storage complex, thus playing a pivotal role in ferritinophagy. In this study, we reported a novel von Hippel-Lindau-based NCOA4 degrader, V3, as a potent ferroptosis inhibitor with an intracellular ferrous iron inhibition mechanism. V3 significantly reduced NCOA4 levels and downregulated intracellular ferrous iron (Fe2+) levels, thereby effectively suppressing ferroptosis induced by multiple pathways within cells and alleviating liver damage. This research presents a chemical knockdown tool targeting NCOA4 for further exploration into intracellular ferrous iron in ferroptosis, offering a promising therapeutic avenue for ferroptosis-related acute liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- School of Pharmacy, Jiangsu Health Vocational College, Nanjing 210009, Jiangsu, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Qidong You, Zhengyu Jiang
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Science Fund for Distinguished Young Scholars of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Ji, J., Jin, Y., Ma, S., Zhu, Y., Bi, X., You, Q., & Jiang, Z. (2024). Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition. Journal of Medicinal Chemistry, 67(15), 12521-12533. https://doi.org/10.1021/acs.jmedchem.4c00403
Vancouver
Ji J, Jin Y, Ma S, Zhu Y, Bi X, You Q, et al. Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition. Journal of Medicinal Chemistry. 2024;67(15):12521-12533. doi:10.1021/acs.jmedchem.4c00403
BibTeX
@article{Ji2024,
author = {Ji, Jian'ai and Jin, Yuhui and Ma, Sinan and Zhu, Yuxuan and Bi, Xinyu and You, Qidong and Jiang, Zhengyu},
title = {Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {15},
pages = {12521--12533},
doi = {10.1021/acs.jmedchem.4c00403}
}
EUVIMED